BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics (NASDAQ:MNPR) had its target price upped by analysts at BTIG Research from $104.00 to $117.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 23.73% from the stock’s previous close.

MNPR has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Chardan Capital restated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a report on Monday, March 30th. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, UBS Group set a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $108.75.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $94.56 on Tuesday. The firm has a market cap of $633.55 million, a price-to-earnings ratio of -49.77 and a beta of 1.52. The stock’s 50-day moving average is $62.99 and its 200-day moving average is $62.16. Monopar Therapeutics has a one year low of $29.18 and a one year high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. On average, equities analysts expect that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets lifted its stake in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $65,000. JPMorgan Chase & Co. grew its position in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Monopar Therapeutics during the 2nd quarter worth about $80,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.